Objectives To determine the indirect consequences of the COVID-19 pandemic on paediatric healthcare utilisation and severe disease at a national level following lockdown on 23 March 2020. Design National retrospective cohort study. Setting Emergency childhood primary and secondary care providers across Scotland; two national paediatric intensive care units (PICUs); statutory death records. Participants 273 455 unscheduled primary care attendances; 462 437 emergency department attendances; 54 076 emergency hospital admissions; 413 PICU unplanned emergency admissions requiring invasive mechanical ventilation; and 415 deaths during the lockdown study period and equivalent dates in previous years. Main outcome measures Rates of emergency care consultations, attendances and admissions; clinical severity scores on presentation to PICU; rates and causes of childhood death. For all data sets, rates during the lockdown period were compared with mean or aggregated rates for the equivalent dates in 2016–2019. Results The rates of emergency presentations to primary and secondary care fell during lockdown in comparison to previous years. Emergency PICU admissions for children requiring invasive mechanical ventilation also fell as a proportion of cases for the entire population, with an OR of 0.52 for likelihood of admission during lockdown (95% CI 0.37 to 0.73), compared with the equivalent period in previous years. Clinical severity scores did not suggest children were presenting with more advanced disease. The greatest reduction in PICU admissions was for diseases of the respiratory system; those for injury, poisoning or other external causes were equivalent to previous years. Mortality during lockdown did not change significantly compared with 2016–2019. Conclusions National lockdown led to a reduction in paediatric emergency care utilisation, without associated evidence of severe harm.
Aim: Spatial turnover in plant species composition reflects the interplay between species’ environmental requirements and their dispersal dynamics. However, its origins are also historical, arising from speciation, extinction and past range dynamics. Here, we test the effects of current environmental gradients and geographical distance on regional species turnover. Using a new approach, we then interpret residual turnover patterns, unexplained by these factors.Location: Native vegetation in the wheatbelt of the Southwest Australian Floristic Region (SWAFR).Methods: We fitted a generalized dissimilarity model of species turnover across 650 floristic inventory plots as a function of current climate, topography, soils and inter‐plot distances. We then decomposed the model errors into independent axes of residual variation, representing unexplained species turnover. We mapped the spatial patterns evident on the main residual axes, and interpreted these using ancillary data on the life form and geographical ranges of associated species, the distributions of some major habitat types, and anomalies between recent and Last Glacial Maximum (LGM) climate.Results: Soil and climatic variables (especially phosphorus and wet quarter precipitation) made sizeable independent contributions to explaining deviance in species turnover, whereas deviance explained by inter‐plot distances and climate co‐varied strongly. Total explained deviance was 34%. Analyses of residual dissimilarity highlighted unexplained floristic similarity among many southern plots. A secondary residual axis highlighted unexplained variation in a broadly westerly to easterly direction. Consistent trends in the life form and geographical ranges of associated species suggest that these patterns are climate‐related. LGM climatic anomalies were correlated with patterns on the second residual axis.Main conclusions: Current soil and climatic gradients are important drivers of floristic turnover in the SWAFR. However, residual analyses revealed broad‐scale gradients in floristic composition unexplained by these variables. These appear to reflect imperfect modelling of the effects of current and perhaps historical climate on species turnover.
This article reviews the latest evidence pertaining to childhood sleep disordered breathing (SDB), which is associated with negative neurobehavioural, cardiovascular and growth outcomes. Polysomnography is the accepted gold standard for diagnosing SDB but is expensive and limited to specialist centres. Simpler tests such as cardiorespiratory polygraphy and pulse oximetry are probably sufficient for diagnosing obstructive sleep apnoea (OSA) in typically developing children, and new data-processing techniques may improve their accuracy. Adenotonsillectomy is the first-line treatment for OSA, with recent evidence showing that intracapsular tonsillectomy results in lower rates of adverse events than traditional techniques. Anti-inflammatory medication and positive airway pressure respiratory support are not always suitable or successful, although weight loss and hypoglossal nerve stimulation may help in select comorbid conditions.Educational aims: To understand the clinical impact of childhood sleep disordered breathing (SDB). To understand that, while sleep laboratory polysomnography has been the gold standard for diagnosis of SDB, other diagnostic techniques exist with their own benefits and limitations. To recognise that adenotonsillectomy and positive pressure respiratory support are the mainstays of treating childhood SDB, but different approaches may be indicated in certain patient groups.
7 November 2022 in Journal for ImmunoTherapy of Cancer
Background Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease. Bispecific T cell engagers (TCEs) targeting prostate-specific membrane antigen (PSMA) and CD3 on T cells showed great clinical potential for the treatment of mCRPC. However, cytokine release syndrome (CRS) and poor pharmacokinetic (PK) profile hinder their further development. To overcome these challenges, Janux has developed JANX007, a tumor-activated T cell engager (TRACTr) with enhanced safety and PK properties. JANX007 is a humanized trispecific protein that contains PSMA- and CD3-binding domains, an albumin binding domain to extend circulating half-life, and a CD3 inhibitory peptide mask fused to the molecule through tumor protease cleavable linker. Only when tumor-resident proteases cleave the TRACTr and enable mask separation can the resulting active molecule bind CD3. This cleavage-dependent CD3 agonism can potentially limit systemic toxicity associated with broad T cell activation. Methods Peptide masks against the CD3 binding domain were identified via phage display. Mask efficiency was evaluated using human CD3 ELISAs. Masking and cleavable linker stability was characterized in human (healthy and mCRPC donor) and cynomolgus monkey serum. JANX007-induced cleavage-dependent activation of T cells was evaluated in human PBMC/prostate tumor cell in vitro co-culture assays. The pharmacokinetic and safety profile of JANX007 was evaluated in non-human primate (NHP) studies. Results Engagement of CD3 target by JANX007 was shown to be cleavage dependent where masking reduced CD3 binding by >600x. In vitro, JANX007 exhibited a ~500x decrease in potency to activate T cells and induce T cell-mediated tumor cell killing relative to non-masked TCE. JANX007 was highly stable in healthy and mCRPC human donor serum, with ≤1% cleavage per day. While proteolytic cleavage of JANX007 in the tumor microenvironment is expected to drive anti-tumor activity, the maintenance of masking in the blood compartment is expected to mitigate the safety risks associated with potential off-tumor toxicity and CRS. JANX007 was found to be highly stable in NHPs with minimally detectable cleavage. The lack of TCE accumulation in NHPs mitigated on-target healthy tissue toxicities and minimized CRS. Clinical chemistry, hematology, and pathology data package support No-Observed-Adverse-Effect-Level (NOAEL) ≥1.5 mg/kg/dose. Finally, the cleavable albumin-binding domain extended the circulating half-life of JANX007 to ~120h in NHPs, relative to the 2h half-life of non-masked TCE, supporting its projected once-weekly clinical dosing. Conclusions Cleavage-dependent activity, half-life extended PK, the potential for superior safety and manufacturability properties of JANX007 support its further development as an attractive mCRPC therapeutic. Acknowledgements We acknowledge Marque Todd for providing insightful comments and help with the interpretation of NHP safety studies. Ethics Approval All animal experiments were approved by the Institutional Animal Use and Care Committee of the institutions conducting the studies and in compliance with the Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals, and the Office of Laboratory Animal Welfare.